Auxilium (AUXL) Could Be Worth Up to $45/Share in a Potential Takeover - Jefferies

Jefferies analyst Thomas Wei weighed in on Auxilium Pharmaceuticals (NASDAQ: AUXL) after Endo offered to acquire the company for $28.10 per share. Wei sees more upside in a potential deal.

He commented, "Although this represents a 30+% premium to AUXL's last closing price, we believe AUXL has a higher value as a standalone company with a $34 price target and believe Endo’s own proposed synergies would justify an even higher takeout price. We can get to valuations of $34-45/share under a takeout scenario"

The firm maintained a Buy rating and price target of $34 on AUXL.

For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.

Shares of Auxilium Pharmaceuticals closed at $21.52 yesterday.

You May Also Be Interested In

• Azul (AZUL) Said in Talks With Gol (GOL) Shareholder for Stock-Based Deal - Bloomberg
• 23andMe (ME) announces CEO’s intention to pursue a potential take-private
• 23andMe (ME) stock jumps as CEO plans to take company private